Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin
- PMID: 30005997
- DOI: 10.1016/j.euf.2018.06.018
Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin
Abstract
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.
Keywords: Bacillus Calmette-Guérin; Bladder cancer; Shortage.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
